Racecadotril 10 & 30 mg sache

  • Racecadotril 10 & 30 mg sache 1
  • Racecadotril 10 & 30 mg sache 2
Product Description

n Racecadotril is a guideline-recommended treatment to alleviate symptoms of acute diarrhoea1, 2, 3. Safety profile is similar to that of placebo. Racecadotril inhibits the degradation of enkephalins, which in turn have potent antisecretory activity but only little effect on motility in the gut in contrast to loperamide (IMODIUM®)4, 5, 6.n Resolution of symptoms with racecadotril when compared to loperamide is associated with less rebound constipation and less abdominal discomfort7.n Reduction of water and electrolytes losses in children suffering from acute diarrhoea8, 9.n Racecadotril is indicated for the complementary symptomatic treatment of acute diarrhoea in infants aged over 3 months10, 11

Read more Show less

ATHENA PHARMACEUTIQUES S.A.S

  • FR
  • 2022
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Pharmaceutical company
Primary activities
Finished Formulation products Distributor/Buyer
View company profile
Categories
more categories Show less

ATHENA PHARMACEUTIQUES S.A.S

  • FR
  • 2022
    On CPHI since
  • 2
    Certificates
  • 500 - 999
    Employees
Company types
Pharmaceutical company
Primary activities
Finished Formulation products Distributor/Buyer
View company profile

More Products from ATHENA PHARMACEUTIQUES S.A.S (14)

  • Fenofibrate 160 , 200 & 267 mg

    Product Fenofibrate 160 , 200 & 267 mg

    Fenofibrate is a third generation fibric acid practically insoluble in water, making it challenging to consistently achieve therapeutic levels1, 2. Micronization technology dramatically improves the dissolution rate-limited gastrointestinal absorption.
  • Ibuprofen 200 & 400 mg Orodispersible tablet

    Product Ibuprofen 200 & 400 mg Orodispersible tablet

    Rated as the safest non-steroidal anti-inflammatory Drug by spontaneous adverse drug reaction reporting in the UK1, 2.n Prominent analgesic & antipyretic activities particularly useful in the management of pain related to dysmenorrhea, headache, postoperative dental pain and rheumatoid arthritis3....
  • Levocetirizine 5 mg Orodispersible tablet

    Product Levocetirizine 5 mg Orodispersible tablet

    n Levocetirizine efficacy superior to loratadine, desloratadine and fexofenadine3, 4, 5, 6, 7, 8.n 43% saving on the social cost of persistent allergic rhinitis9.n Minimal impairment of memory and psychomotor functioning nor mood changes after acute and sub chronic administration of levocetirizine10.
  • Meloxicam 7.5 mg & 15 mg Orodispersible tablet

    Product Meloxicam 7.5 mg & 15 mg Orodispersible tablet

    Meloxicam appears to have better gastrointestinal tolerance than non-selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) thanks to its preferential inhibition of COX-2 vs. COX-1. The Orodispersible tablets enhance patient compliance, administration without water and accuracy of dosage
  • Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    Product Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    n Prednisolone is highly effective and signifi cantly more effective that Non-Steroidal Anti-Infl ammatory Drugs (NSAIDs) in rheumatoid arthritis and may be used intermittently1.n Prednisolone is the active metabolite of prednisone and prednisone’s effi cacy is related to the patient’s hepatic fu...
  • Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    Product Prednisolone 1mg & 5mg Orally Disintegrating Tablet

    Prednisolone is highly effective and signifi cantly more effective that Non-Steroidal Anti-Infl ammatory Drugs (NSAIDs) in rheumatoid arthritis and may be used intermittently1.n Prednisolone is the active metabolite of prednisone and prednisone’s effi cacy is related to the patient’s hepatic func...
  • Secnidazole 2 mg sachet

    Product Secnidazole 2 mg sachet

    Next-generation 5-nitroimidazole prodrug granted priority review by the FDA with longer half-life (17h) allowing for a once-daily dosing.n Secnidazole has similar activity against the range of microorganisms associated with bacterial vaginosis compared to metronidazole or tinidazole whilst sparin...
  • Tramadol 37.5 mg + Paracetamol 325 mg

    Product Tramadol 37.5 mg + Paracetamol 325 mg

    Fixed-combination of two well-known and established analgesics, devoid of the gastrointestinal, cardiovascular and renal adverse events associated with Non-Steroidal Anti-inflammatory Drugs (NSAIDs) responsible for 3.500-16.500 death per year in the USA1, 2.n Fixed-dose combination treatment redu...
  • Zolpidem 5 & 10 mg Orodispersible tablet

    Product Zolpidem 5 & 10 mg Orodispersible tablet

    Zolpidem is particularly suitable for insomniac patient suffering with difficulties with sleep initiation
  • Bilastine 10 mg & 20 mg

    Product Bilastine 10 mg & 20 mg

    1. Bilastine is a potent, effective antihistamine, without sedation, without cardiac toxicity, it has absence of metabolism and does not interact with cytochrome P4502.2. In experimental models, Bilastine has shown an excellent dose-dependent activity when administered by oral or intravenous rout...
  • Domperidone 10 mg Orodispersible Tablet

    Product Domperidone 10 mg Orodispersible Tablet

    Selective D2/D3 dopamine antagonist.n Combine prokinetic and anti-emetic activities on gastrointestinal tract making it an ideal agent for treating gastroparesis (postprandial fullness, nausea, vomiting and stomach fullness). Does not cross the blood-brain barrier minimizing CNS adverse events
  • Donepezil 5 & 10 mg OroDispersible Tablet

    Product Donepezil 5 & 10 mg OroDispersible Tablet

    Lesser behaviour deterioration vs. Galantamine14.n Superior Global Responder Rate vs. Galantamine14.n Lower risk of treatment withdrawals for any reason or because of an adverse event for Donepezil vs. Rivastigmine or Galantamine14
show all 14 other products

ATHENA PHARMACEUTIQUES S.A.S resources (1)

  • Navigating the Drug Delivery Device Development Process

    Video Navigating the Drug Delivery Device Development Process

    The purpose of this section, is to give to the audience some advice and warnings on how to better develop and produce a customized drug delivery medical device, based on our own experience. in fact the pathway for a new drug delivery medical device, is full of the unexpected and sometimes the company has to stop the development phase so they never get to production or they spend a lot more money and time compared to a better path/arrangement. There will be also examples and case studies taken from our own experience. The other purpose of this section, is to show you the advantages of a customer centric and multidisciplinary approach to develop and produce a customized drug delivery device.
    2024-10-15